1994 Nobel Prize in Physiology or Medicine — Gilman and Rodbell, Discovering G Proteins, the Intermediaries of Cell Membrane Signaling

What You'll Learn in This Article

You will gain an understanding of the fundamental mechanisms of how signals from hormones or neurotransmitters, after binding to receptors on the cell surface, are transmitted into the cell. Alfred Gilman and Martin Rodbell discovered and elucidated the mechanism of action of G proteins (GTP-binding proteins), which act as intermediaries between cell membrane receptors and intracellular enzymes. We will explore how this discovery laid the foundation for the current era of GPCR (G protein-coupled receptor) drugs, which are the target of 30-40% of prescribed medications today, and how it opened up a broader understanding of a wide range of pathologies, from cholera and whooping cough to diabetes and mental disorders.

Beyond Common Knowledge — The Intermediary Between Signal and Response

The story of cell signaling begins with Earl Sutherland, who won the Nobel Prize in 1971. Sutherland demonstrated that when a hormone (the first messenger) binds to a receptor on the cell surface, cAMP (the second messenger) is produced inside the cell, triggering a response. The concept that the signal does not cross the cell membrane and that an intermediate mediates the signal to the cell interior.

However, there was a mystery. The receptor and the cAMP-generating enzyme (adenylyl cyclase) are located in different places. How does the receptor activate the enzyme? There must be an intermediary between the two.

Rodbell's discovery in the 1970s: The energy molecule called GTP (guanosine triphosphate) plays a crucial role between the receptor and the enzyme. He provided experimental evidence that GTP is essential for signaling in the cell membrane.

Gilman's breakthrough (1980s): He actually isolated and purified this intermediary protein to identify it. He named this protein G protein (GTP-binding protein). He also discovered that G protein consists of three subunits: alpha, beta, and gamma, and that it switches between active and inactive states through changes in its binding state with GTP and GDP.

The complete picture of cell signaling is as follows:

1. Signal molecule (first messenger) — e.g., adrenaline, serotonin, dopamine, histamine, opioids, even light (opsin receptor). 2. GPCR (G protein-coupled receptor) — a receptor protein that spans the cell membrane seven times. 3. G protein — switches from GDP state (inactive) to GTP state (active); the alpha subunit dissociates and moves. 4. Effector enzyme — adenylyl cyclase (cAMP production), phospholipase C (IP3, DAG production), ion channel (direct opening/closing). 5. Second messenger — cAMP, IP3, DAG, Ca2+, etc., trigger intracellular responses. 6. Cellular response — muscle contraction, gene expression, metabolic changes, nerve excitation, etc.

In the language of computer science, this is remarkably similar to the API gateway's authorization token system. The GPCR is the gateway that receives external requests. Upon receiving a request, it converts the authorization token (G protein) from GDP (expired state) to GTP (valid state). The alpha subunit, which has a valid token, dissociates and activates the downstream effector services. When GTP hydrolyzes back to GDP, the token expires, terminating the signal.

The strength of this system is signal amplification. Activation of a single receptor activates multiple G proteins, each G protein activates multiple effectors, and each effector produces many second messengers. A single hormone molecule can trigger tens of thousands of downstream reactions – a system of amplification.

The Landscape of the Era — Democratization in Africa and a Crisis in Korea's Infrastructure Safety

1994 was a year in which the lights and shadows of human history were starkly contrasted.

In world history, May 10 marked the inauguration of Nelson Mandela as President of South Africa – his story of becoming president after 27 years of imprisonment symbolized the end of apartheid. On the other hand, the Rwandan genocide occurred from April 6 to July – 800,000 people were killed in 100 days due to Hutu extremists' massacre of Tutsis. The world watched. The pinnacle and abyss of humanity coexisted in the same year.

In technological history, December 15 saw the release of Netscape Navigator, popularizing the web. January 1 marked the entry into force of NAFTA, a symbol of global free trade. May 6 saw the opening of the Channel Tunnel, connecting Great Britain and continental Europe. IBM released the PowerPC processor.

In Korean history, July 8 marked the death of Kim Il-sung – ending his 46-year reign and completing the succession to Kim Jong-il. October 21 saw the collapse of the Seongsu Bridge, killing 32 people on their way to school. This event exposed the vulnerability of the hastily built social infrastructure of the development era. This was followed by the Sampoong Department Store collapse (1995) and the Sewol ferry disaster (2014), marking a lineage of safety-neglecting accidents. The Ji-jeon-pa incident in September, followed by the Daegu subway fire and the C-Land fire, marked the beginning of a trend of social safety crises. In October, the KEDO was established, an international organization for cooperation in resolving the North Korean nuclear issue.

In this year of contrasts, the Nobel Committee recognized the two individuals who elucidated the fundamental intermediaries of cell signaling. In a year when the connection between signal and response was starkly divided in international politics and society, the system that accurately transmits signals within cells was recognized.

Alfred Gilman — A Name Destined for Pharmacology

Alfred G. Gilman (1941-2015) was an American pharmacologist. His name itself is intertwined with pharmacology.

His father earned a Ph.D. in biochemistry from Yale University and served as a professor at Yale University School of Medicine, and at Yale, he became very close to Professor Louis S. Goodman, so he named his son's middle name Goodman. Furthermore, his father and Professor Goodman co-authored the first edition of "The Pharmacological Basis of Therapeutics," the "standard textbook of pharmacology." This textbook has become the standard for pharmaceutical education worldwide and is still used today. Gilman himself later edited the 6th edition, and he said that he felt his name had predetermined his destiny.

He grew up in a privileged environment. His father was very musically talented and played instruments at concerts as a hobby, and his mother was a pianist. His grandfather ran a musical instrument store, and his maternal grandfather was a trombone player. Most of his family was musically gifted, and he developed a musical sensibility in this environment. He stopped playing music when he left the band at Yale.

He earned his Ph.D. from Case Western Reserve University in 1969, and from 1971 to 1981, he was a professor at the University of Virginia, and from 1981, he was a professor at the University of Texas (Dallas). He performed the crucial experiment of isolating and purifying the alpha subunit of G protein.

Martin Rodbell — 40 Years of Research at NIH

Martin Rodbell (1925-1998) was an American biologist. He earned his Ph.D. from the University of Washington in 1954 and served as a researcher at the National Institutes of Health (NIH) from 1956 to 1985. He worked as a researcher at the National Institute of Environmental Health Sciences (NIEHS) from 1986 to 1994, and he died four years after winning the Nobel Prize.

Rodbell's key contribution was experimentally demonstrating in the 1970s that GTP is essential for cell membrane signaling. Through his research on the signaling of adrenaline receptors in fat cells and liver cells, he established that there is an intermediate that uses GTP between the receptor and the effector enzyme.

Rodbell and Gilman achieved complementary discoveries in different laboratories. Rodbell's conceptual discovery (GTP-mediated signaling) was completed by Gilman's discovery of the substance (G protein isolation and purification). The two researchers' work combined to create a complete picture of the G protein system.

The Decisive Discovery — The Substance of G Protein and the Secret of Cholera Toxin

Gilman's experiment, in which he first isolated G protein, was decisive. He sequentially purified the active component needed for adrenaline receptor signaling in the cell membrane and confirmed that the substance is a protein that binds to GTP. He also discovered that this protein consists of three subunits: alpha, beta, and gamma, and that the alpha subunit has a GTP/GDP binding site.

What was particularly decisive was the cholera toxin experiment. Cholera is caused by a toxin secreted by the bacterium. Gilman and Rodbell discovered that cholera toxin chemically modifies the alpha subunit of G protein (ADP-ribosylation) to prevent GTP hydrolysis. As a result, G protein is permanently fixed in an active state. This means that the cAMP-generating enzyme on the cell membrane is continuously activated, causing a continuous increase in cAMP inside the cell. In intestinal epithelial cells, this causes a large amount of salt and water to be secreted, leading to severe dehydrating diarrhea. The molecular mechanism of death from cholera.

On the other hand, the toxin of whooping cough inhibits a different type of G protein, causing persistent coughing. The two bacterial toxins manipulate different points in the G protein system to cause pathology.

These experiments clearly demonstrated that the G protein system actually exists and that its manipulation is the cause of actual pathology.

CS Framework — API Gateway and Authorization Token System

If we reconstruct G protein signaling in the language of computer science, we get the following diagram.

GPCR = API Gateway: The GPCR on the cell membrane is the gateway that receives external requests (hormones, neurotransmitters, light). Each GPCR has an interface specification that responds only to specific ligands.

G protein = Authorization Token: The alpha subunit of G protein is a token that switches between GDP (inactive) and GTP (active) states. GDP = expired token (inactive), GTP = valid token (active).

Ligand binding = Authentication Request Received: When a ligand binds to the GPCR, the gateway receives an authentication request and activates the G protein (GDP → GTP exchange).

Alpha subunit dissociation = Issuance of a Valid Token: The activated alpha subunit dissociates from beta and gamma and moves to the downstream service. This is like a request proxy with a valid token moving to the backend.

Effector Activation = Downstream Service Call: Alpha-GTP activates adenylyl cyclase (cAMP production), phospholipase C (IP3, DAG production), ion channel (direct opening/closing), etc.

GTP hydrolysis = Token Expiration: The alpha's intrinsic GTPase activity converts GTP back to GDP. The token automatically expires, terminating the signal. This automatic expiration mechanism limits the duration of the signal.

Cholera toxin = Expiration Prevention Attack: Cholera toxin chemically modifies the alpha subunit to prevent GTP hydrolysis. The token is permanently fixed in a valid state. As a result: adenylyl cyclase is continuously active → cAMP is continuously produced → large amounts of salt and water are secreted from intestinal epithelial cells → dehydrating diarrhea.

Target Drugs = GPCR-Specific Ligand Design: Today, 30-40% of prescribed medications target GPCRs. For example:

• Beta-blockers (propranolol, atenolol) — block β-adrenergic receptor GPCR, cardiovascular
• H2 blockers (cimetidine, ranitidine) — block histamine H2 GPCR, stomach acid
• Opioids (morphine, codeine) — activate μ-opioid receptor GPCR, pain relief
• Tricyclic antidepressants, SSRIs — affect serotonin receptor GPCR
• Antipsychotics (risperidone, aripiprazole) — block dopamine D2 receptor GPCR
• Sartans — block angiotensin II receptor GPCR, hypertension
• Incretin agents (GLP-1 agonists - semaglutide/Ozempic) — activate GLP-1 receptor GPCR, diabetes/obesity

This analogy is not perfect. Cells have multiple GPCRs and G proteins operating in parallel, and various signaling cascades are intertwined. It is a much more complex network than a simple gateway-token model.

Academic Impact: The Age of GPCRs and the Targeted Drug Market

This discovery fundamentally reshaped cell signaling, pharmacology, and medicine.

Expansion of the GPCR Family: It was discovered that approximately 800 GPCR genes exist in the human genome. Today, a significant portion of olfaction, gustation, and vision is attributed to GPCRs (2004 Nobel Prize for Axel and Buck, for the discovery of olfactory receptors).

Elucidation of GPCR Structure: After the 2000s, the three-dimensional structure of GPCRs was revealed through X-ray crystallography and cryo-electron microscopy. In 2012, Robert Lefkowitz and Brian Kobilka were awarded the Nobel Prize in Chemistry for their research on GPCR structure and signaling.

Absolute Landscape of Drug Development: Today, 30-40% of global prescription drug sales target GPCRs. These include a wide range of clinical areas such as cardiovascular, psychiatric, pain, gastrointestinal, and endocrine disorders.

Recent Issue: Explosive Growth of the Incretin Series:

• Semaglutide (Ozempic/Wegovy, 2017) — GLP-1 receptor GPCR agonist, used to treat type 2 diabetes and obesity. Became one of the hottest drugs in the world in the 2020s, and is significantly changing the socio-cultural landscape, particularly as an obesity treatment.
• Tirzepatide (Mounjaro/Zepbound, 2022) — GLP-1/GIP dual agonist, with a more potent weight loss effect.

Expanded Understanding of Disease: It was revealed that G protein abnormalities are involved in various pathologies.

• Cholera and Pertussis (toxins modify G proteins)
• Diabetes (incretin GPCR signaling abnormalities)
• Alcohol Addiction (dopamine signaling)
• Psychiatric Disorders (dopamine and serotonin receptor abnormalities)
• Hereditary Endocrine Disorders (G protein gene mutations)
• Some Tumors (G protein activating mutations)

The Korean Connection and Today

The impact of this lineage in Korea is widespread. Since the late 1990s, research on GPCRs and G proteins has been active in cell biology and pharmacology laboratories at Seoul National University, Yonsei University, KAIST, POSTECH, and Seoul Asan Hospital.

Expansion of Clinical Applications: Today, most Korean adults are taking at least one drug that targets a GPCR. These include β-blockers and ARBs (angiotensin II receptor blockers) for hypertension, H2 blockers for gastrointestinal medications, opioids for many pain relievers, and SSRIs for depression and anxiety. Recently, semaglutide (Ozempic/Wegovy), a diabetes and obesity treatment, has garnered explosive interest in Korea.

Korean Drug Development: Recent drug development in Korea has been active, with companies like Yuhan Corporation (Rexazy, an EGFR-targeted anticancer drug) and Hanmi Pharmaceutical (Rolontis, a treatment for neutropenia) developing new drugs, many of which target GPCRs. Korea is among the top countries in the world in GPCR crystal structure research (e.g., Seoul National University, KAIST).

Psychiatric Pharmacology: Drugs targeting GPCRs of neurotransmitters such as dopamine, serotonin, and GABA are the standard treatment for schizophrenia, depression, anxiety disorders, and obsessive-compulsive disorders. Korean clinical guidelines for psychiatric disorders are based on this lineage.

Why is it Important?

What the two scientists left behind is the established principle that "GTP-using mediators serve as switches at the fundamental level of cell signaling."

Cell biology, pharmacology, and medicine are being reorganized around this discovery. Without understanding cell membrane signaling, we cannot explain why most of today's drugs work. It is a fundamental concept in undergraduate biology and pharmacology.

A case of two independent studies achieving complementary completion. Rodbell's conceptual discovery and Gilman's discovery of the entity combined to create a complete picture. They explored different axes in their respective laboratories, but their discoveries converged.

Inheritance of the Tradition of Pharmacology Textbooks: The story of the son inheriting and updating the pharmacology textbook co-authored by his father, Goodman, is symbolic. It is a special narrative that intertwines the inheritance of academic knowledge and personal fate.

After this award, the flow of GPCR and signaling research continued as follows:

• 2000, Karlson, Grinard, and Kandel — Neural signaling
• 2004, Axel and Buck — Discovery of olfactory receptor GPCRs
• 2012, Lefkowitz and Kobilka (Chemistry) — Elucidation of GPCR structure
• 2021, Patapoutian and Julius — Temperature and tactile receptors (TRPV, etc., ion channel type)

Clinical and industrial applications of this discovery:

• 30-40% of targeted drugs: β-blockers, H2 blockers, SSRIs
• Diabetes and obesity treatments: Semaglutide (Ozempic), Tirzepatide (Mounjaro) — major hits of the era
• GPCR crystal structure-based drug design: Standard for precision drug design since the 2010s
• Olfactory and gustatory receptor research: Applied to the food and fragrance industries

→ Previous: 1993 — Roberts and Sharp → Next: [1995 — Batch 8 in progress]